Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch study from secukinumab or ixekizumab to risankizumab in plaque psoriasis
2019-000904-14Phase 3Unknown
- Sponsor
- AbbVie Inc.
- Start
- Sep 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of risankizumab in plaque psoriasis and psoriasis, sponsored by AbbVie Inc. Primary endpoint: Proportion of subjects achieving static Physician's Global Assessment clear (0) or almost clear (1) response at Week 16. Status: unknown.
02
Drugs
risankizumab
03
Conditions
plaque psoriasispsoriasis
Beyond the preview
Go deeper on 2019-000904-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000904-14.